MARAbio utilizes a maternal blood test to detect the presence of specific autoantibodies associated with Maternal Autoantibody Related Autism (MARA), achieving over 90% predictive accuracy for severe autism in children before clinical symptoms appear. This early detection enables healthcare providers to implement tailored interventions, improving outcomes for affected families.
Funding
$25.1M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Maternal Autoantibody Related Autism (MARA) often goes undetected until clinical symptoms appear in children, delaying the implementation of tailored interventions that could improve outcomes. Early detection is hindered by the lack of accessible and accurate diagnostic tools available before or shortly after birth.
Solution
MARAbio offers a maternal blood test designed to detect specific autoantibodies associated with MARA, providing a predictive assessment of a child's likelihood of developing severe autism. The test can be administered before pregnancy or as early as birth, enabling healthcare providers to identify potential cases of MARA before clinical symptoms manifest. By identifying these cases early, clinicians can initiate timely and tailored interventions, potentially mitigating the most severe effects of autism and improving outcomes for affected families. The company's technology provides an early assessment with a high degree of predictive accuracy.
Target Audience
The primary target audience includes healthcare providers, expecting mothers, and women planning to become pregnant who want to assess the risk of Maternal Autoantibody Related Autism (MARA) in their children.
Features
- Maternal blood test to identify specific autoantibodies linked to MARA.
- Predictive assessment of a child's likelihood of developing severe autism.
- Testing available before pregnancy or as early as birth.
- High predictive accuracy (over 90%) for severe autism in children with a positive MARA test in the mother.